-$0.43 Earnings Per Share Expected for Intellia Therapeutics Inc (NTLA) This Quarter

Wall Street brokerages forecast that Intellia Therapeutics Inc (NASDAQ:NTLA) will post ($0.43) earnings per share for the current quarter, Zacks Investment Research reports. Four analysts have made estimates for Intellia Therapeutics’ earnings. The highest EPS estimate is ($0.28) and the lowest is ($0.49). Intellia Therapeutics posted earnings of ($0.31) per share in the same quarter last year, which would indicate a negative year over year growth rate of 38.7%. The company is scheduled to announce its next earnings report on Tuesday, March 13th.

On average, analysts expect that Intellia Therapeutics will report full-year earnings of ($1.68) per share for the current year, with EPS estimates ranging from ($1.74) to ($1.53). For the next year, analysts anticipate that the firm will report earnings of ($1.94) per share, with EPS estimates ranging from ($2.34) to ($1.52). Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Intellia Therapeutics.

Intellia Therapeutics (NASDAQ:NTLA) last issued its earnings results on Tuesday, October 31st. The company reported ($0.44) EPS for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.06. Intellia Therapeutics had a negative return on equity of 28.01% and a negative net margin of 215.92%. The business had revenue of $7.30 million during the quarter, compared to analyst estimates of $5.83 million. During the same period in the previous year, the company posted ($0.22) EPS. The firm’s revenue was up 49.0% compared to the same quarter last year.

NTLA has been the subject of a number of recent research reports. Jefferies Group set a $42.00 price objective on Intellia Therapeutics and gave the stock a “buy” rating in a report on Tuesday, October 31st. Leerink Swann boosted their price objective on Intellia Therapeutics from $29.00 to $37.00 and gave the stock an “outperform” rating in a report on Tuesday, October 31st. They noted that the move was a valuation call. Barclays reissued a “buy” rating on shares of Intellia Therapeutics in a report on Sunday, November 5th. ValuEngine lowered Intellia Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, November 15th. Finally, Oppenheimer reissued a “hold” rating on shares of Intellia Therapeutics in a report on Tuesday, December 12th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and four have given a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $30.17.

In other news, CEO Nessan Bermingham sold 111,500 shares of the business’s stock in a transaction that occurred on Wednesday, December 6th. The stock was sold at an average price of $20.34, for a total value of $2,267,910.00. Following the transaction, the chief executive officer now owns 696,000 shares in the company, valued at approximately $14,156,640. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Institutes For Biomed Novartis sold 1,523,000 shares of the business’s stock in a transaction that occurred on Tuesday, December 12th. The stock was sold at an average price of $18.30, for a total value of $27,870,900.00. The disclosure for this sale can be found here. Insiders have sold a total of 1,971,283 shares of company stock valued at $37,137,161 over the last three months. Corporate insiders own 12.80% of the company’s stock.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Schwab Charles Investment Management Inc. lifted its stake in Intellia Therapeutics by 58.6% in the second quarter. Schwab Charles Investment Management Inc. now owns 42,674 shares of the company’s stock valued at $683,000 after purchasing an additional 15,771 shares during the last quarter. Rhumbline Advisers purchased a new position in Intellia Therapeutics in the second quarter valued at approximately $275,000. State of Wisconsin Investment Board purchased a new position in Intellia Therapeutics in the second quarter valued at approximately $160,000. SG Americas Securities LLC purchased a new position in Intellia Therapeutics in the second quarter valued at approximately $101,000. Finally, Bank of New York Mellon Corp lifted its stake in Intellia Therapeutics by 73.0% in the second quarter. Bank of New York Mellon Corp now owns 54,802 shares of the company’s stock valued at $876,000 after purchasing an additional 23,126 shares during the last quarter. Hedge funds and other institutional investors own 48.95% of the company’s stock.

Shares of Intellia Therapeutics (NASDAQ NTLA) opened at $20.16 on Thursday. Intellia Therapeutics has a 12-month low of $10.83 and a 12-month high of $33.34. The company has a market capitalization of $853.48 and a PE ratio of -13.01.

COPYRIGHT VIOLATION NOTICE: “-$0.43 Earnings Per Share Expected for Intellia Therapeutics Inc (NTLA) This Quarter” was first posted by BBNS and is owned by of BBNS. If you are viewing this article on another website, it was copied illegally and reposted in violation of United States and international copyright laws. The correct version of this article can be accessed at https://baseballnewssource.com/markets/0-43-earnings-per-share-expected-for-intellia-therapeutics-inc-ntla-this-quarter/1824468.html.

About Intellia Therapeutics

Intellia Therapeutics, Inc is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene.

Get a free copy of the Zacks research report on Intellia Therapeutics (NTLA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Intellia Therapeutics (NASDAQ:NTLA)

Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Report: Eduardo Nunez and Red Sox Agree to Deal for One Year
Report: Eduardo Nunez and Red Sox Agree to Deal for One Year
Los Angeles Angels Plan to Use Shohei Ohtani in Six-Man Rotation
Los Angeles Angels Plan to Use Shohei Ohtani in Six-Man Rotation
Cubs Sign Free Agent Yu Darvish
Cubs Sign Free Agent Yu Darvish
Mother of Pittsburgh Pirates Player Elias Diaz Has Been Kidnapped
Mother of Pittsburgh Pirates Player Elias Diaz Has Been Kidnapped
Giants Will Retire No. 25 of Barry Bonds in August
Giants Will Retire No. 25 of Barry Bonds in August
Mookie Betts Awarded Arbitration of $10.5 Million
Mookie Betts Awarded Arbitration of $10.5 Million


Leave a Reply

 
© 2006-2018 BBNS.